ArticleAnnals of hematology2011
Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.
Article in Annals of hematology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02686593 (Clofarabine, Cytarabine and Mitoxantrone), which is not on this map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML
Who cites it
5 citing papers in PubMed, 18 citations in OpenAlex.
- Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation.Cancer medicine · 2020Trial
- Feasibility of Outpatient Follow-Up After High-Dose Cytarabine Consolidation in Patients With Acute Myeloid Leukemia.Cureus · 2026Article
- Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.Current hematologic malignancy reports · 2014Review
- High-dose cytarabine (HD araC) in the treatment of leukemias: a review.Current hematologic malignancy reports · 2013Review
- Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.British journal of haematology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clofarabine (40 mg/m(2)/day × 5) and high-dose cytosine arabinoside (Ara-C, 1-2 g/m(2)/day × 5) were used in 10 men and 11 women, at a median age of 45 (22-62) years, with refractory (N = 4) and relapsed (N = 17) acute myeloid leukaemia, after a median of 3 (2-5) prior regimens. Grade 4 myelosuppression was observed in all cases, with two patients dying of bacterial sepsis. Nine patients achieved a complete remission. Disease status, number of prior therapies, and cytogenetic aberrations were not associated with the outcome. However, remission was only achieved with Ara-C at 2 g/m(2)/day and not 1 g/m(2)/day (9/15 versus 0/4, P = 0.03).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.